clinical trial · NCT07765498
A Study of LY4355756 in Healthy Participants
Eli Lilly and Company·phase1·recruiting·n = 123
HealthyLY4355756LY4355756Midazolam
brief summary
The purpose of the study is to assess how LY4355756 is absorbed by the body and how safe it is to healthy participants. There will be four inpatient stays at the clinical research unit (CRU). For Part A there will be 5 continuous days, Part B 22 continuous days, Part C 5 continuous days in each of the 3 periods, and Part D 18 continuous days in the CRU.
started
Aug 17, 2026
primary completion
Jan 1, 2027
completion
Jan 1, 2027
last updated
Oct 8, 2026
official title
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY4355756 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol